Fortress Biotech (FBIO) Net Income towards Common Stockholders (2010 - 2026)

Fortress Biotech's Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$6.2 million for Q4 2025.

• In Q4 2025, Net Income towards Common Stockholders rose 35.79% year-over-year to -$6.2 million; the TTM figure through Dec 2025 stood at -$1.9 million (up 96.63% YoY), while the FY2025 annual figure was -$1.9 million, up 96.63% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at -$6.2 million, down from $3.7 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $13.4 million in Q2 2025, with the low at -$59.9 million in Q4 2021.
• The 5-year median for Net Income towards Common Stockholders is -$20.6 million (2022), against an average of -$22.2 million.
• The sharpest annual moves came in 2021 and 2025: Net Income towards Common Stockholders tumbled 128.48% in 2021, then soared 200.12% in 2025.
• Fortress Biotech's Net Income towards Common Stockholders stood at -$59.9 million in 2021, then soared by 51.62% to -$29.0 million in 2022, then surged by 61.02% to -$11.3 million in 2023, then increased by 14.49% to -$9.7 million in 2024, then surged by 35.79% to -$6.2 million in 2025.
• Business Quant data shows FBIO's Net Income towards Common Stockholders at -$6.2 million in Q4 2025, $3.7 million in Q3 2025, and $13.4 million in Q2 2025.